99% Lenvatinib  (E7080)  417716-92-8  Multi-target Inhibitor

Product Name: Lenvatinib (E7080) 
Synonyms: 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide;E7080;E7080 (Lenvatinib);Lenvatinib (E7080);ER-203492-00;1-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea;4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide XEN445;E70801-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea 
CAS: 417716-92-8 
MF: C21H19ClN4O4 
MW: 426.85 
Usage E7080 (Lenvatinib) is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively. 

Lenvatinib

Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. Lenvatinib is used for the treatment of differentiated thyroid cancer that is either locally recurrent ormetastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine).LENVATINIB is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat thyroid cancer and kidney cancer. Compare kinase inhibitors.

Uses

Lenvatinib is a prescription medication used to treat people with differentiatedthyroid cancer (DTC, a type of thyroid cancer) that can no longer be treated with radioactive iodine and is progressing.

Lenvima is also used in combination with everolimus in patients with advanced renal cell carcinoma who had previously received an anti-angiogenic therapy.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.